By Fineline Cube Sino Biopharmaceutical (HKG: 1177) announced that TRD205, a Category 1 innovative drug self-developed by its subsidiary Tide Pharmaceutical, has completed Phase II clinical trials for chronic post-surgical neuropathic pain (CPSNP) and received Breakthrough Therapy Designation from China’s National Medical Products Administration (NMPA).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Designation Type | Breakthrough Therapy Designation |
| Product | TRD205 (Category 1 innovative drug) |
| Indication | Chronic post-surgical neuropathic pain (CPSNP) |
| Trial Phase Completed | Phase II |
| Development Status | Subsidiary Tide Pharmaceutical; Sino Biopharmaceutical (HKG: 1177) |
Drug Profile & AI-Driven Innovation
- Molecule: Highly selective AT2R antagonist (oral)
- Discovery Platform: Second-generation artificial intelligence (AI) drug discovery platform
- Innovation: “Target-driven de novo generation” strategy using only 3D geometric features and physicochemical properties of AT2R target pocket as inputs
- Intellectual Property: Global patents held by Sino Biopharmaceutical covering AI-generated molecular structure and synthesis pathway
Mechanism of Action – Dual-Pathway Peripheral Analgesia
| Pathway | Mechanism | Clinical Benefit |
|---|---|---|
| Peripheral Immune Modulation | Inhibits macrophage migration to injury site, downregulating neurotransmitters, ROS, and inflammatory cytokines | Reduces peripheral sensitization without CNS effects |
| Neural Transmission Blockade | Inhibits pain-related ion channels (Nav1.8, TRPV1) in dorsal root ganglion (DRG) | Blocks nerve impulse transmission at source |
| Safety Profile | Exclusively peripheral nervous system action | Avoids CNS side effects (drowsiness, dizziness); addresses long-term tolerability challenges |
The AI platform’s novel approach generated entirely new molecules from massive chemical space without relying on known ligand structures, representing a significant advancement in de novo drug design methodology.
Market Impact & Unmet Need
- Chronic Pain Treatment Gap: Current therapies suffer from poor long-term tolerability due to CNS side effects; TRD205’s peripheral-only mechanism directly addresses this critical limitation
- Competitive Edge: First highly selective AT2R antagonist with dual-mechanism peripheral analgesia and AI-generated novel molecular structure
- Strategic Positioning: Positions Sino Biopharmaceutical as a leader in AI-driven pain therapeutics with potential global commercial opportunities in the $80B+ chronic pain market
Forward‑Looking Statements
This brief contains forward‑looking statements regarding TRD205’s clinical development and regulatory pathway. Actual results may differ due to risks including Phase III trial outcomes, final regulatory decisions, and competitive dynamics.-Fineline Info & Tech